Pharmaceutical TechnologyOriginal article
Tremfya rescues J&J’s immunology sales to fuel strong Q3
EarningsTremfyaPositive
AI Analysis
Summary
J&J reported strong Q3 results driven by Tremfya's immunology sales performance and raised its 2026 guidance, despite headwinds from generic and biosimilar competition to other products.
Financial Highlights
Guidance
raised for 2026
Importance:6/10
Sentiment:
0.60
immunologysales growthQ3 earningsguidance raisegenerics pressurebiosimilars
Related Companies
Read the original article
Published by Pharmaceutical Technology on October 13, 2026 2:34 PM